Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Alex Thompson maintained a Buy rating on Oruka Therapeutics (ORKA) with a $150 price target. The firm's healthcare specialist has a strong track record, boasting a 46.9% average return and 70.92% success rate. Meanwhile, the broader analyst consensus for Orka remains a Strong Buy, with an average price target of $148.20.
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Oruka Therapeutics today and set a price target of $150.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Thompson CFA covers the Healthcare sector, focusing on stocks such as Cullinan Management, Spyre Therapeutics, and Oruka Therapeutics. According to TipRanks, Thompson CFA has an average return of 46.9% and a 70.92% success rate on recommended stocks.
Oruka Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $148.20.